fbpx
Connect with us

BUSINESS

A Lot Going On For Marapharm Ventures Inc (OTCMKTS:MRPHF)

Published

on

Since a string of legislations legalizing medical marijuana around North America came into operation, demand is up. Companies are jostling for the opportunity to meet this demand. In light of this, Marapharm Ventures Inc (OTCMKTS:MRPHF) announced an operating agreement with Full Spectrum Medicinal Inc. (“FSM”).

Strategic alliance

As per the press release, the strategic alliance hopes to attract more revenue. In the long run, the two companies hope to bring more value to their investors. The partnership will “set the standard for premium quality cannabis.” By coming together, the companies will reduce labor requirements for pot cultivation. This is due to the fact that the firms will jointly pursue system re-engineering and grow their plants organically.

Linda Sampson, CEO of Marapharm Ventures Inc (OTCMKTS:MRPHF) is one particularly happy person. She believes the alliance will appropriately leverage their resources and experience to feed the growing demand. In her words:

“As a Canadian based company, we are confident about the demand and anticipated size of the Canadian cannabis market. This strategic alliance is mutually beneficial and will bring great shareholder value.”

The Marapharm Ventures Inc (OTCMKTS:MRPHF) partnership to increase product quality

The partnership will see the companies utilize all waste from cannabis cultivation to generate power. According to the release, the companies will employ a Vapor Thermal Carbonization System (VTCS) to optimize their energy consumption. This way, as per the press release, “… we will meet and exceed the curriculum of organic consumption.”

Further, the Canadian cannabis giant announced an update on “the status of permitting for final occupancy and continued cultivation in the temporary buildings.” According to the announcement, an onsite contractor will complete occupancy requirements “as quickly as possible.”

As the company anticipates their transition to full operation, Kurt Keating, Director of Operations provided an important update.

Achievable objectives

The DO confirmed that the existing crops are doing well. To meet the demand cycle, Keating explained that: “We are preparing our core genetics for propagation by increasing our plant count…”

Further, the DO said:

“We’re greatly anticipating our transition to full production. Our cultivation and compliance teams are building the future for Marapharm each day. Our objective is grand and achievable; we will focus on classic, award winning, and new varieties for the Vegas market all cultivated under certified organic protocol to ensure customer satisfaction and safety.”

Continue Reading
Advertisement

BUSINESS

Dosecann Inc, A Subsidiary Of Auxly Cannabis Group Inc (OTCMKTS:CBWTF), Enters A Pact With Lonza Group AG (OTCMKTS:LZAGF) For LEMS Machine And Capsule Filling And LEMS Technology

Published

on

Auxly Cannabis Group Inc (OTCMKTS:CBWTF)’s subsidiary Dosecann Inc has signed a pact with Lonza Group AG (OTCMKTS:LZAGF)’s subsidiary Capsugel Inc. As per the terms of the accord, Dosecann receives rights to use sealing LEMS and capsule filling LEMS technology. The company also gets equipment for capsule sealing and filling besides proprietary liquid filled Licaps capsules of Lonza. Dosecann collaborates with Lonza for new formulations to produce Cannabis capsules.

Lonza’s technology in health applications

Lonza’s technology is used in functional improvements such as odor and taste masking, bioavailability enhancement, controlled/ delayed release, and combination products in nutritional and health applications.

Annual capacity for 200 million capsules

Dosecann will equip its PEI facility with a complete production line having an annual capacity to fill/ seal 200 million Capsugel Licaps capsules. It can provide new compounds having improved functionality.

Dosecann will improve its production and product development capabilities by getting access to patented technologies of Lonza. The company will also use the patented technology to support the differentiated product offerings via possibilities of color and branding and multiple delivery systems. The new technologies of Lonza will enable Dosecann to introduce differentiated and innovative capsule products in different dosages.

President of Auxly, Hugo Alves said the company is thrilled to work with an international leader in encapsulation technology and capsules. He looks forward to develop a fruitful and creative long-term relationship with Capsugel and Lonza. It is the right time for the deal because Auxly is preparing to market derivative products with expected legalization by end of this year.

Auxly focuses marijuana derivatives

Auxly is focusing on marijuana derivatives expansion by end of this year despite widening its net loss. The company has reported revenues of $817,000 CAD in Q1 2019. The company has derived sales of $525,000 CAD from deferred service contracts contributed by KGK Sciences. It has generated balance sales of $292,000 CAD from cannabis flower. The company is holding back the dried flower to produce concentrates, edibles, and topicals expecting legalization by Health Canada by October 2019. Its net loss has widened to $13.8 million CAD in Q1 2019 from $10.5 million CAD in Q1 2018.

Continue Reading

BUSINESS

Real Brands Inc (OTCMKTS:RLBD) Signs An LOI To Purchase Proprietary CBD Formulas From Florida Based Integrative Medicine US

Published

on

Real Brands Inc (OTCMKTS:RLBD) has signed an LOI to buy proprietary CBD formulas of Integrative Medicine US. The formulas comprise ancient Chinese Medicine and Herbal Remedies that are blended CBD, nutrients, and endocannabinoid systems. Following the acquisition, Real Brands will use the formulas in its CBD Pharmacy brand. The company will use the new logo with a Chinese Symbol of healing.

CBD Pharmacy products

The initial product launch of CBD Pharmacy comprise salves, tinctures, balms, powders, and capsules developed to treat pain and promote relaxation, and boost immunity and energy.

Jerry Pearring, Chief Executive Officer of Real Brands, said medicinal herbs, CBD, and vitamins are blended using a proprietary formula to develop innovative medicine by Jonathan M. Fields, the founder of Integrative Medicine. The new products will help to keep the Real Brands in the driver’s seat to create a strong brand for CBD Pharmacy.

According to Pearring, CBD Pharmacy is expected to satisfy the growing consumer demand for hemp derived cannabidiol products. Consumers will also enjoy the benefits of eastern medical therapies.

Jonathan said the recent technological advances helped the company to develop superior medicinal products. Its features include Vegan, 100% Non-GMO, and tested in a third-party lab using cannabidiol. The company developed delivery mechanisms so that customers can get CBD and other ingredients in the right dosage to provide the desired effect for long-time.

Partners with Scot Piercy

Real Brands has partnered with Scot Piercy, a professional athlete, in April 2019. He will act as an ambassador for Real Brands Team and invested in the company last month. Pearring commenting the partnership said the company is excited to announce Scot as an ambassador. The investment shows the belief in the business model of the company and the long-term prospects. Pearring is pleased to welcome Scot on board Real Brands.

Piercy said he is proud to join the team of Real Brands. He studied about Real Brands and provides the support to grow hemp derived cannabidiol brands. Piercy further said it is looking forward to work with the company to introduce unique brands of Real Brands through e-commerce sites and retail channels.

Continue Reading

BUSINESS

Hexo Corp (NYSEAMERICAN:HEXO) Acquisition Of Newstrike Brands Finalized

Published

on

Acquisition now Finalized

Hexo Corp (NYSEAMERICAN:HEXO) has announced that it has completed the acquisition of all of Newstrike Brands’ issued and outstanding securities totaling 558,971, 064 marking the finalization of the acquisition process. The company has also received regulatory approval from relevant authorities including the high court further stamping the deal.

Reportedly, Newstrike Brands’ board of directors voted enthusiastically in favor of the acquisition that saw each of Newstrike’s stock exchanged for 0.06332 of Hexo’s share. Following the completion of the acquisition process, is expected to be delisted from TSX exchange platform as it will now operate under its new owner- Hexo.

Increased Production Space and Capacity

Popular voices in the industry believe that the $263 million acquisition sets Hexo among the industry’s elite. Among the several befits Hexo stands to gain from the acquisition includes additional production space estimated at 470,000 sqft. This is a significant addition to the company’s existing 1.3 million sqft.

With additional growing space comes increased production capacity. It is estimated that Hexo’s annual production capacity will surge from the current 110,000 kilos annually to a whopping 150,000 kilos annually which obviously translates to revenue influx.

Hexo’s CEO, Sebastien St-Louis said that “The combination of these two talented teams, both pioneers in the cannabis industry, will accelerate Hexo’s vision of creating the best cannabis technology company.” He adds that the Hexo is now commencing journey on the next phase of its progress.

The acquisition enhances the company’s solid position in the Canadian cannabis space and opening it up to countless possibilities abroad. The company already announced plans to set up operation in Greece as it seeks to seize the upcoming European market. Plans are also underway to set up operations in South America, the U.S (which is expected to open up fully by 2020), and more other locations.

The company already adjusted its 2020 revenue outlook to an optimistic $400 million. This projection factors in the company’s now bigger size in terms of production capacity and market access considering Hexo now assumes Newstrike’s distribution agreements with strategic partners across 8 Canadian provinces.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories